AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric Intraocular Lens (IOL) Clinical Study in Japan
Not Applicable
Completed
- Conditions
- Cataracts
- Interventions
- Device: AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL
- First Posted Date
- 2011-03-28
- Last Posted Date
- 2018-07-02
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 65
- Registration Number
- NCT01323777
- Locations
- 🇯🇵
Tokyo Dental College Suidobashi Hospital, Chiyoda-ku, Tokyo, Japan
🇯🇵Hayashi Eye Hospital, Fukuoka, Japan
Nepafenac 0.3% Two Study
Phase 2
Completed
- Conditions
- Cataract
- Interventions
- Drug: Nepafenac Ophthalmic Suspension, 0.3%Drug: Nepafenac Ophthalmic Suspension, 0.1%Other: Nepafenac Vehicle 0.3%
- First Posted Date
- 2011-03-18
- Last Posted Date
- 2012-12-17
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 1342
- Registration Number
- NCT01318499
- Locations
- 🇺🇸
Contact Alcon Call Center for Trial Locations, Fort Worth, Texas, United States
AL-54478 Proof of Concept Study
Phase 2
Completed
- Conditions
- Open-angle Glaucoma (OAG)Ocular Hypertension (OHT)
- Interventions
- First Posted Date
- 2011-03-18
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 64
- Registration Number
- NCT01318252
Safety and Intraocular Pressure (IOP) Lowering Effect of AL-59412C
Phase 2
Terminated
- Conditions
- Open-angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2011-03-10
- Last Posted Date
- 2013-10-25
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 4
- Registration Number
- NCT01312454
A Multi-Site Post Marketing Surveillance Study for Systane in Indian Patients
Phase 4
Completed
- Conditions
- Moderate to Severe Dry Eye
- Interventions
- Other: Systane
- First Posted Date
- 2011-03-09
- Last Posted Date
- 2012-02-02
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 300
- Registration Number
- NCT01311609
Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension
Phase 3
Completed
- Conditions
- Open-Angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2011-03-09
- Last Posted Date
- 2014-03-06
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 771
- Registration Number
- NCT01310777
Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension
Phase 3
Completed
- Conditions
- Open-Angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2011-03-07
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 1184
- Registration Number
- NCT01309204
ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients
Phase 1
Completed
- Conditions
- Exudative Age-Related Macular Degeneration
- Interventions
- Biological: Ranibizumab 0.5 mgBiological: ESBA1008 solution
- First Posted Date
- 2011-02-25
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 376
- Registration Number
- NCT01304693
A Comparison of Visual Function After Bilateral Implantation of Presbyopia Correcting Intraocular Lenses
Not Applicable
Completed
- Conditions
- Cataract
- Interventions
- Device: ReSTOR +3Device: LENTIS MPlus
- First Posted Date
- 2011-02-18
- Last Posted Date
- 2012-10-23
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 24
- Registration Number
- NCT01299155
- Locations
- 🇪🇸
Contact Alcon Call Center for Trial Locations, Oviedo, Asturias, Spain
Divided Dose of TRAVATAN®
Phase 2
Completed
- Conditions
- Open-angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2011-02-18
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 67
- Registration Number
- NCT01298687
© Copyright 2025. All Rights Reserved by MedPath